NASDAQ:VIR
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.'s revenue fell 7.6% in fiscal 2025 to $68.6M while operating margin rose to −699.2%. Free cash flow was −$396.6M, −578.5% of revenue, and the diluted share count rose 1.7%.Summary generated from Vir Biotechnology, Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$68.6M
Revenue growth−7.6%
Revenue, 5-yr CAGR−2.1%
Gross margin100.0%
Operating margin−699.2%
Net margin−638.9%
ROICn/a
Return on equity−45.7%
Debt / equityn/a
Free cash flow−$396.6M
FCF margin−578.5%
Share count change+1.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,095 | 1,616 | 86 | 74 | 69 |
| Operating income | 421 | 833 | −684 | −587 | −479 |
| Net income | 529 | 516 | −615 | −522 | −438 |
| Free cash flow | −69 | 1,595 | −800 | −454 | −397 |
Recent filings
- 8-KOther events
Oct 8, 2026 - 8-KDirector or officer change
Oct 1, 2026 - 4Insider transaction report
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jul 24, 2026 - 4Insider transaction report
Jun 10, 2026 - 8-KDirector or officer change
Jun 10, 2026